Clinical trials: Non Small Cell Lung Cancer Stage III
NSCLC
JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
The Phase II study is a multi-center, open, dose escalation and dose extension clinical trial. It is planned to enroll 24 patients; the phase III study is a multi-center, randomized, double-blind, placebo-controlled clinical…
- Trial name
- NCT04874844
- Testing
- Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)
- Volunteers
- 420 people
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Advanced Squamous Non Small Cell Lung Cancer
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT05840016
- Testing
- AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel
- Where
- China
- Volunteers
- 532 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
This is a phase Ib, multi-center, open label study evaluating the safety and efficacy of CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC who have progressed after EGFR TKI treatment.
- Trial name
- NCT03758287
- Testing
- CT053PTSA, Gefitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Double Blind
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
This is a multicenter Phase II/III study evaluating the efficacy and safety of SCTB41 combined with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment in patients with driver-negative locally…
- Trial name
- NCT07662395
- Testing
- SCTB41, Tislelizumab, Paclitaxel
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Sinocelltech Ltd.
Non-small Cell Lung Cancer (NSCLC)
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT07154706
- Testing
- Taletrectinib
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 180 people
- Sponsor
- Nuvation Bio Inc.
Non-Small-Cell Lung Cancer
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer…
- Trial name
- NCT00049998
- Testing
- topotecan
- Where
- 114 sites in Australia, Austria and 29 more
- Volunteers
- 760 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Carcinoma
FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma
This is an open-label, randomized phase II trial of a monoclonal antibody (mAb) drug immunoconjugate, SGN-15, administered weekly in combination with weekly docetaxel.
- Trial name
- NCT00086333
- Testing
- SGN-15, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Seagen Inc.
Carcinoma, Non-Small-Cell Lung
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery.
- Trial name
- NCT06012435
- Testing
- sigvotatug vedotin, docetaxel
- Where
- 331 sites in United States, Argentina and 23 more
- Volunteers
- 762 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Non-Small Cell Lung Cancer
SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ
This is a randomized, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of SYS6010 versus docetaxel in participants with Locally Advanced or Metastatic EGFR Wild-type Non-squamous…
- Trial name
- SYNSTAR03 (NCT07442565)
- Testing
- SYS6010, Docetaxel
- Volunteers
- 506 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Non-Small Cell Lung Cancer
A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of bevacizumab (Avastin) versus placebo in combination with carboplatin/paclitaxel in participants with advanced or recurrent…
- Trial name
- NCT01364012
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 17 sites in China
- Volunteers
- 276 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected…
- Trial name
- MERMAID-1 (NCT04385368)
- Testing
- Durvalumab + SoC chemotherapy
- Where
- 140 sites in United States, Argentina and 31 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive…
- Trial name
- NCT02838420
- Testing
- Alectinib, Crizotinib
- Where
- 19 sites in China, South Korea and 1 more
- Volunteers
- 187 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
The purpose of the study was to evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or…
- Trial name
- SOLAR (NCT02588261)
- Testing
- naquotinib mesilate, Erlotinib, Gefitinib
- Where
- 167 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Lung Cancer, Non-Small Cell, Non-Small-Cell Lung Cancer
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one…
- Trial name
- NCT00065182
- Testing
- Topotecan/Docetaxel combination, Docetaxel
- Where
- 85 sites in United States, Canada and 1 more
- Volunteers
- 399 people
- Sponsor
- GlaxoSmithKline
Melanoma (Skin), Non-Small-Cell Lung Carcinoma
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
From Protocol v3.0 dated 16Jun2022. This is an international, multicenter, open-label, multiple cohort, First in Human, phase 1b clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any…
- Trial name
- NCT04990479
- Testing
- GAd-PEV, MVA-PEV
- Where
- 7 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Nouscom SRL
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Non-Small Cell Lung Cancer
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations
- Trial name
- NCT04248829
- Testing
- Lazertinib 240 mg/160 mg, Gefitinib 250 mg
- Where
- 80 sites in Australia, Greece and 11 more
- Volunteers
- 393 people
- Sponsor
- Yuhan Corporation
Advanced Non-Small Cell Lung Cancer
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT06980272
- Testing
- SSGJ-707, Pembrolizumab
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin +…
- Trial name
- NCT02367794
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody, Carboplatin, Nab-Paclitaxel
- Where
- 242 sites in United States, Argentina and 24 more
- Volunteers
- 1,021 people
- Sponsor
- Hoffmann-La Roche
NSCLC (Non-small Cell Lung Carcinoma)
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
The primary objectives of this study were to evaluate the safety and tolerability of itacitinib in combination with docetaxel and to select doses for further evaluation (Part 1, safety run-in portion), and to evaluate and compare…
- Trial name
- NCT02257619
- Testing
- Itacitinib, docetaxel
- Where
- 16 sites in United States
- Volunteers
- 9 people
- Sponsor
- Incyte Corporation